Immatics NV
IMTX
Company Profile
Business description
Immatics NV is a clinical-stage biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies. The company derives its maximum revenue from United States.
Contact
Paul-Ehrlich-Strasse 15
TubingenBW72076
DEUT: +49 707153970
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
407
Stocks News & Analysis
stocks
ASX gold miner under pressure to sell by activist investor
Activist investor presses gold miner on selling to larger players.
stocks
Ask the Analyst: Will Amcor lose its dividend aristocrat status?
When consistency becomes constraint.
stocks
Chart of the Week: We see opportunity in this beaten down industrial player
The market sees risks and are discounting the shares excessively.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,916.90 | 58.60 | -0.65% |
| CAC 40 | 8,230.77 | 80.35 | 0.99% |
| DAX 40 | 24,942.05 | 146.11 | 0.59% |
| Dow JONES (US) | 51,302.30 | 615.23 | 1.21% |
| FTSE 100 | 10,327.50 | 4.80 | -0.05% |
| HKSE | 25,253.40 | 379.81 | -1.48% |
| NASDAQ | 26,623.32 | 230.65 | -0.86% |
| Nikkei 225 | 67,470.69 | 931.45 | -1.36% |
| NZX 50 Index | 13,101.61 | 13.47 | -0.10% |
| S&P 500 | 7,539.90 | 13.78 | -0.18% |
| S&P/ASX 200 | 8,686.10 | 59.50 | -0.68% |
| SSE Composite Index | 4,057.78 | 26.19 | -0.64% |